An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-la Roche sponsored pertuzumab study
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab; Vinorelbine
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 05 Feb 2015 Planned End Date changed from 1 Jan 2025 to 1 Feb 2025 as reported by ClinicalTrials.gov record.
- 05 Feb 2015 Planned primary completion date changed from 1 Jan 2025 to 1 Feb 2025 as reported by ClinicalTrials.gov record.
- 19 Dec 2014 New trial record